{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_16792", "batch_size": 260, "batch_pos": 57, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 2, "answer": "no", "rationale": "The segment neutrally reports vaccine development efforts.", "method": "llm_batch", "batch_id": "batch_2_6268", "batch_size": 260, "batch_pos": 46, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 3, "answer": "no", "rationale": "The segment discusses vaccine development efforts.", "method": "llm_batch", "batch_id": "batch_3_14884", "batch_size": 260, "batch_pos": 28, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 4, "answer": "no", "rationale": "The segment reports factual information about vaccine development, without posing a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_15756", "batch_size": 260, "batch_pos": 26, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 5, "answer": "no", "rationale": "The segment describes vaccine development as a 'precautionary measure,' lacking explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_11380", "batch_size": 260, "batch_pos": 24, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word used in conjunction with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_13968", "batch_size": 260, "batch_pos": 10, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 7, "answer": "no", "rationale": "The segment discusses vaccine development but contains no bare negation.", "method": "llm_batch", "batch_id": "batch_7_11736", "batch_size": 260, "batch_pos": 7, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
{"Q": 8, "answer": "yes", "rationale": "Describes ongoing development capability ('executives... are already developing or about to test sample human vaccines').", "method": "llm_batch", "batch_id": "batch_8_9576", "batch_size": 260, "batch_pos": 229, "statement_text": "Executives at three vaccine manufacturers GSK Plc Moderna Inc and CSL Seqirus, owned by CSL Ltd - told Reuters they are already developing or about to test sample human vaccines that better match the circulating subtype, as a precautionary measure against a future pandemic.", "article_id": 1272}
